The effect of acetylcysteine and bromhexine on the improvement and prevention of hospitalization in outpatients with Covid-19
Phase 3
- Conditions
- covid-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20220302054167N1
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 225
Inclusion Criteria
Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test
Oxygen level 98-92%
Exclusion Criteria
• Dissatisfaction of the patient or their relatives to participate in the study
• Pregnancy and lactation
Evidence of pulmonary involvement and the need for hospitalization or referral to an infectious disease specialist
Prohibition of N-acetylcysteine and bromhexine as a history of allergy and anaphylactic shock
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood Oxygen. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: pulse oximeter.;Cough. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Shortness of breath. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Sore throat. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.
- Secondary Outcome Measures
Name Time Method Time to recover from the desired symptoms. Timepoint: daily. Method of measurement: questionnaire.;Duration of hospitalization. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.;Death. Timepoint: At the beginning of the study (before the intervention) and 7, 14 days. Method of measurement: questionnaire.